


**Table S1.** Multi variable treatment related cox regression distant metastasis free survival analysis.


Variables		N	Hazard ratio - 95% CI	P-value
Age		3302	0.83 (0.77 – 0.90)	<b>&lt;0.01</b>
Gender	Male	2030 (61)	Reference	
	Female	1302 (39)	0.83 (0.74 - 1.06)	0.19
WHO	0 - 1	2792 (84)	Reference	
	2 - 4	59 (11)	1.02 (0.99 - 1.06)	0.20
Melanoma type	SSM	2246 (67)	Reference	
	NM	1086 (33)	1.32 (1.20 – 1.45)	<b>&lt;0.01</b>
Ulceration	Absent	1825 (55)	Reference	
	Present	1191 (36)	1.12 (1.09 – 1.15)	<b>0.04</b>
Breslow Thickness	0.1 – 1.0mm	457 (14)	Reference	
	1.0 – 2.0 mm	948 (29)	0.91 (0.79 – 1.04)	0.18
	2.0 – 4.0mm	1064 (32)	1.01 (0.91 – 1.15)	0.07
	>4.0mm	863 (26)	1.25 (1.18 – 34)	<b>0.01</b>
Satellite lesions	Absent	2635 (79)	Reference	
	Present	334 (10)	0.98 (0.97 – 1.01)	0.18
Dermal mitosis	Absent	307 (9)	Reference	
	Present	1850 (56)	0.94 (0.93 – 0.95)	<b>&lt;0.01</b>
BRAF mutation	Absent	1058 (33)	Reference	
	Present	2116 (66)	0.96 (0.89 – 1.02)	0.19
NRAS mutation	Absent	1916 (77)	Reference	
	Present	582 (23)	0.98 (0.91 – 1.05)	0.55



**Figure S1.** Kaplan Meier curve distant metastasis free survival analysis demonstrating the cumulative survival of NM (red) versus SSM (blue).

**Table S2.** Multi variable treatment related cox regression progression free survival analysis in patients treated with immune checkpoint inhibition.


Variables		N	Hazard ratio - 95% CI	P-value
Age		2104	1.00 (0.99 – 1.00)	0.91
Gender	Male	1333	Reference	
	Female	771	0.83 (0.70 – 0.97)	<b>0.02</b>
WHO	0 - 1	1902	Reference	
	2 - 4	79	1.02 (0.98 – 1.05)	0.32
Treatment type	Anti-CTLA-4	462	Reference	
	Ant-PD-1 / Anti-CLTA-4	1642	0.91 (0.81 – 1.02)	0.10
LDH	Not elevated	1609	Reference	
	Elevated	458	1.22 (1.13 – 1.32)	<b>&lt;0.01</b>
Cerebral disease	Absent	1713	Reference	
	Present	351	1.05 (1.01 - 1.11)	<b>0.03</b>
Total organ sites	<3	678	Reference	
	>2	1137	1.01 (0.87 - 1.20)	0.82
Melanoma	SSM	1357	Reference	
	NM	747	0.87 (0.74 – 1.02)	0.09
BRAF mutation	Absent	1053	Reference	
	Present	916	0.85 (0.74 – 0.97)	<b>0.02</b>
NRAS mutation	Absent	1112	Reference	
	Present	574	1.12 (1.01 – 1.24)	<b>0.03</b>



**Figure S2.** Kaplan Meier curve progression free survival analysis demonstrating the cumulative survival of NM (red) versus SSM (blue) patients treated with immune checkpoint inhibition.

**Table S3.** Multi variable treatment related cox regression progression free survival analysis in patients treated with immune checkpoint inhibition.

Variables		N	Hazard ratio - 95% CI	P-value
Age		2104	1.00 (0.99 – 1.00)	0.91
Gender	Male	1333	Reference	
	Female	771	0.83 (0.70 – 0.97)	<b>0.02</b>
WHO	0 - 1	1902	Reference	
	2 - 4	79	1.02 (0.98 – 1.05)	0.32
Treatment type	Anti-CTLA-4	462	Reference	
	Ant-PD-1 / Anti-CLTA-4	1642	0.91 (0.81 – 1.02)	0.10
LDH	Not elevated	1609	Reference	
	Elevated	458	1.22 (1.13 – 1.32)	<b>&lt;0.01</b>
Cerebral disease	Absent	1713	Reference	
	Present	351	1.05 (1.01 - 1.11)	<b>0.03</b>
Total organ sites	<3	678	Reference	
	>2	1137	1.01 (0.87 - 1.20)	0.82
Melanoma	SSM	1357	Reference	
	NM	747	0.87 (0.74 – 1.02)	0.09
BRAF mutation	Absent	1053	Reference	
	Present	916	0.85 (0.74 – 0.97)	<b>0.02</b>
NRAS mutation	Absent	1112	Reference	
	Present	574	1.12 (1.01 – 1.24)	<b>0.03</b>



**Figure S3.** Kaplan Meier curve survival analysis demonstrating the cumulative survival of NM (red) versus SSM (blue) patients treated with immune checkpoint inhibition.